Entresto 24 MG-26 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26F3TQN
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,949
Award facts
- Contract value 100% obligated
- $10,948.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,948.82 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (60-count packages) on January 14, 2026, with an ultimate completion date of January 15, 2026. This non-set-aside contract utilizes firm fixed-price pricing and is being performed at the awardee's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, regularly fulfills federal medical procurement needs through competitive awards with the DLA Medical Supply Chain. Entresto, a combination medication containing sacubitril and valsartan, is a specialty pharmaceutical product primarily used in cardiology for heart failure treatment. The company's extensive portfolio of federal contract awards demonstrates its capability to efficiently deliver diverse pharmaceutical products across multiple therapeutic domains to military treatment facilities, veterans' healthcare programs, and other federal medical institutions. This delivery order represents a routine task order execution under the broader pharmaceutical prime vendor agreement supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F3TQN?
SPE2DR26F3TQN was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F3TQN worth?
The government has obligated $10,949 on SPE2DR26F3TQN.
Is contract SPE2DR26F3TQN an order under another contract?
Yes. SPE2DR26F3TQN is a delivery order under SPE2DR25D2104, an indefinite delivery contract.
Was contract SPE2DR26F3TQN competed?
The extent of competition for SPE2DR26F3TQN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award